Search Results
Sep 01, 2026, 11:37 ET A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
current developments this week include: Conexeu Sciences Inc. (Nasdaq: CNXU), Establishment Labs Holdings Inc. (NASDAQ: ESTA), Evolus, Inc. (NASDAQ: EOLS), InMode Ltd. (NASDAQ: INMD), and AbbVie Inc. (NYSE: ABBV).
More news about: Equity Insider
Jul 09, 2026, 08:16 ET One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
landscape that includes public names investors track, such as AbbVie (NYSE: ABBV), Galderma (OTCQB: GALDY), Novo Nordisk (NYSE: NVO), and Evolus (NASDAQ: EOLS), each distinct, and none a proxy for Conexeu.The Catalyst: What P.R.O.O.F MeansP.R.O.O.F, the company's 12-month preclinical
More news about: USA News Group
May 22, 2026, 10:31 ET Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ: CNXU), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Evolus, Inc. (NASDAQ: EOLS), Bioventus Inc. (NASDAQ: BVS), Mesoblast Limited (NASDAQ: MESO)KEY TAKEAWAYSA fresh Nasdaq debut. Conexeu
More news about: USA News Group
Nov 13, 2025, 10:20 ET Component Obsolescence: Trends to Watch in 2026
30 percent of EOLs do not have a product change notification (PCN) issued beforehand, which means the best offense is a good defense. OEMs and their end customers are
More news about: Flip Electronics
Sep 22, 2025, 09:03 ET Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch
BEACH, Fla., Sept. 22, 2025 /PRNewswire/ -- Evolus, Inc. (NASDAQ: EOLS), a leading publicly traded aesthetic beauty company, has named Dr. Benjamin Eskenazi, MD, FACS, founder of Miami
More news about: Avabello Aesthetics